US 7,030,110 B2 · Cyclic oxyguanidine pyrazinones as protease inhibitors

Abstract

Cyclic oxyguanidine pyrazinone compounds are described, including compounds of the Formula I: wherein R3, R4, R5, W, and A are as set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

A method of treating thrombosis in a mammal comprising administering a compound of Formula I to the mammal

or a solvate, hydrate or pharmaceutically acceptable salt thereof;
wherein:
W is hydrogen, R1, R1OCO, R1 CO, R1(CH2)sNHCO, or (R1)2CH(CH2)sNHCO, wherein s is 0–4;
R1is
R2,
R2(CH2)tC(R12)2, where t is 0–3, and each R12 can be the same or different,
(R2)(OR2)CH(CH2)p, where p is 1–4,
(R2)2(OR12)C(CH2)p, where p is 1–4,
R2C(R12)2(CH2)t, wherein t is 0–3, and each R12 can be the same or different, wherein (R12)2 can also form a ring with C represented by C3-7 cycloalkyl,
R2CF2C(R12)2(CH2)q, wherein q is 0–2, and each R12 can be the same or different, wherein (R12)2 can also form a ring with C represented by C3-7 cycloalkyl,
R2CH2C(R12)2(CH2)q, wherein q is 0–2, and each R12 can be the same or different, wherein (R12)2 can also form a ring with C represented by C3-7 cycloalkyl,
(R2)2CH(CH2)r, where r is 0–4 and each R2 can be the same or different, and wherein (R2)2 can also form a ring with CH represented by C3-7 cycloalkyl, C7-12 bicylic alkyl, C10-16 tricylic alkyl, or a 5- to 7-membered mono- or bicyclic heterocyclic ring which can be saturated or unsaturated, and which contains from one to three heteroatoms selected from the group consisting of N, O and S,
R2O(CH2)p, wherein p is 2–4,
(R2)2CF(CH2)r, wherein r is 0–4 and each R12 can be the same different, wherein (R12)2 can also form a ring with C represented by C3-7 cycloalkyl, C7-12 bicyclic alkyl, C10-16 tricyclic alkyl, or a 5- to 7-membered mono- or bicyclic heterocyclic ring which can be saturated or unsaturated, and which contains from one to three heteroatoms selected from the group consisting of N, O and S,
where s is 0 or 1, or
R2CF2C(R12)2;
R2is
phenyl, naphthyl, or biphenyl, each of which is unsubstituted or substituted with one or more of C1-4 alkyl, C1-4 alkoxy, halogen, hydroxy, CF3, OCF3, COOH, CONH2, or SO2NH2,
a 5- to 7-membered mono- or a 9- to 10-membered bicyclic heterocyclic ring or non-heterocyclic ring which can be saturated or unsaturated, wherein the heterocyclic ring contains from one to four heteroatoms selected from the group consisting of N, O and S, and wherein the heterocyclic or non-heterocyclic ring is unsubstituted or substituted with halogen or hydroxy,
C1-7 alkyl, unsubstituted or substituted with one or more of hydroxy, COOH, amino, aryl, C3-7 cycloalkyl, CF3, N(CH3)2, —C1-3alkylaryl, heteroaryl, or heterocycloalkyl,
CF3,
C3-7 cycloalkyl, unsubstituted or substituted with aryl,
C7-12 bicyclic alkyl, or
C10-16 tricyclic alkyl;
R3is
hydrogen, C1-6 alkyl, C3-7 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, optionally substituted C6-10 aryl, optionally substituted C6-10 ar(C1-6)alkyl, optionally substituted heteroaryl, trifluoromethyl, halogen, C1-6 hydroxyalkyl, cyano, nitro, carboxamido, —C2Rx, —CH2ORx or —ORx,
where Rx, in each instance, is independently one of hydrogen, C1-6 alkyl or C3-7 cycloalkyl wherein said alkyl or cycloalkyl groups may optionally have one or more unsaturations;
R4is
hydrogen or halogen;
R12 is
hydrogen,
phenyl, naphthyl, or biphenyl, each of which is unsubstituted or substituted with one or more of C1-4 alkyl, C1-4 alkoxy, halogen, hydroxy, CF3, OCF3, COOH, or CONH2,
a 5- to 7-membered mono- or a 9- to 10-membered bicyclic heterocyclic ring which can be saturated or unsaturated, and which contains from one to four heteroatoms selected from the group consisting of N, O and S,
C1-4 alkyl, unsubstituted or substituted with one or more of hydroxy, COOH, amino, aryl, heteroaryl, or heterocycloalkyl,
CF3,
C3-7 cycloalkyl,
C7-12 bicyclic alkyl, or
C10-16 tricyclic alkyl;
R5 is hydrogen, C1-4alkyl, or C2-4 alkenyl;
A is one of
Ra, Rb and Rc are independently hydrogen, alkyl, hydroxy, alkoxy, aryloxy, aralkoxy, alkoxycarbonyloxy, cyano or —CO2Rw, where
Rw is alkyl, cycloalkyl, phenyl, benzyl,
where Rd and Re are independently hydrogen, C1-6 alkyl, C2-6 alkenyl or phenyl, Rf is hydrogen, C1-6 alkyl, C2-6 alkenyl or phenyl, Rg is hydrogen, C1-6 alkyl, C2-6 alkenyl or phenyl, and Rh is aralkyl or C1-6 alkyl;
each n is from zero to 4;
each m is from zero to 4;
and
each j is from zero to 4;
provided that n, m and j are not all zero.

45 more elements

Cyclic oxyguanidine pyrazinones as protease inhibitors

Life of this patent

Cyclic oxyguanidine pyrazinones as protease inhibitors

Life of this patent

Abstract

Claims28